Quick Answer
CATALYST PHARMACEUTICALS, INC. reported Net Income Loss of $214.33 million for the year ending 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +30.8% in Net Income Loss from 2024 to 2025.
- This data is from CATALYST PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2007 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 19 years of available data (2007 to 2025), CATALYST PHARMACEUTICALS, INC.'s Net Income Loss has grown by 5,277.6%.
- Historical annual values: Fiscal year 2025: $214.33 million | Fiscal year 2024: $163.89 million | Fiscal year 2023: $71.41 million | Fiscal year 2022: $83.08 million | Fiscal year 2021: $39.48 million | Fiscal year 2020: $74.98 million | Fiscal year 2019: $31.88 million | Fiscal year 2018: -$34.00 million | Fiscal year 2017: -$18.41 million | Fiscal year 2016: -$18.07 million | Fiscal year 2015: -$20.23 million | Fiscal year 2014: -$15.51 million | Fiscal year 2013: -$12.15 million | Fiscal year 2012: -$4.08 million | Fiscal year 2011: -$6.39 million | Fiscal year 2010: -$4.01 million | Fiscal year 2009: -$7.24 million | Fiscal year 2008: -$10.56 million | Fiscal year 2007: -$4.14 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: